Skip to content

Author

Andrew Kent

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Engineered TCR therapy targeting lipid antigens in AML 2306228

Acute myeloid leukemia (AML) is the most common form of adult leukemia and has a poor prognosis with a 5-year overall survival of ∼30%. While CAR-T has revolutionized the treatment of other hematological malignancies, it has been difficult to replicate this same success in AML. Healthy myeloid cells often share e...

Amandip Bangar, B. Linden, Andrew Kent et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.